Table 6 Absolute and relative risk by indication and overall (pooled datasets)
From: Suicidality and divalproex sodium: analysis of controlled studies in multiple indications
| Â | Placebo | DVPX | Relative risk | Risk difference per 1,000 subjects | ||
|---|---|---|---|---|---|---|
| Â | n/N | Absolute risk per 1,000 subjects | n/N | Absolute risk per 1,000 subjects | Incidence of events in DVPX subjects/incidence in placebo subjects | Additional DVPX subjects with events |
Placebo-controlled and low-dose-controlled studies | ||||||
Indication: | Â | Â | Â | Â | Â | Â |
Epilepsy | 1/204 | 4.90 | 1/208 | 4.81 | 0.98 | -0.09 |
Psychiatric | 9/726 | 12.40 | 10/926 | 10.80 | 0.87 | -1.60 |
Migraine | 0/196 | 0.00 | 0/324 | 0.00 | - | 0.00 |
Total | 10/1,126 | 8.88 | 11/1,458 | 7.54 | 0.85 | -1.34 |
Placebo-controlled studies | ||||||
Total | 9/992 | 9.07 | 11/1,137 | 8.29 | 0.91 | -0.78 |